Research programme: NR2B NMDA receptor negative allosteric modulators - BioCrea

Drug Profile

Research programme: NR2B NMDA receptor negative allosteric modulators - BioCrea

Alternative Names: NR2B NAMs - BioCrea

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator biocrea GmbH
  • Class Small molecules
  • Mechanism of Action NR2B N-Methyl D-Aspartate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Depressive disorders; Major depressive disorder

Most Recent Events

  • 28 Feb 2018 No recent reports of development identified for research development in Depressive disorders(Treatment-resistant) in Germany
  • 28 Feb 2018 No recent reports of development identified for research development in Major depressive disorder(Treatment-resistant) in Germany
  • 23 Apr 2014 BioCrea is actively seeking to out-license or partner its NR2B NMDA receptor negative allosteric modulators programme as of 23 Apr 2014. http://www.biocrea.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top